Cabergoline in Nonfunctioning Pituitary Adenomas

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

140 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-02-01

Study Completion Date

2017-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Clinically nonfunctioning pituitary adenoma remains the only pituitary tumor subtype for which no effective medical therapy is available or recommended. We will evaluate the use of cabergoline in a clinical trial, in order to define the efficacy of this treatment in nonfunctioning pituitary adenoma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas

NCT01620138

Non-functioning Pituitary Adenomas Prolactinomas

COMPLETED PHASE2/PHASE3

Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas

NCT02288962

Pituitary Neoplasms Adenoma

ACTIVE_NOT_RECRUITING PHASE3

Cabergoline in the Management of Nonfunctioning Pituitary Adenoma

NCT07034859

Pituitary Adenoma MRI RCT

ENROLLING_BY_INVITATION PHASE4

Short and Long Term Efficacy of Combined Cabergoline and Octreotide Treatment in Acromegalic Patients

NCT01014793

Acromegaly

COMPLETED

Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor

NCT00889525

Cushing's Disease Corticotroph Adenoma

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Nonfunctioning pituitary adenomas (NFPA) are common tumors of sellar region characterized by the absence of clinically hormonal pituitary secretion. These adenomas are typically not diagnosed until they become very large and cause compressive neurologic symptons (e.g. visual impairment or cranial nerve palsy). Most of them are able to synthesized gonadotropins but not secreted it.

Transsphenoidal surgical resection is the first-choice therapy in NFPA. However, complete removal is difficult and tumor rest is very common. In these cases, the pragmatic use of radiotherapy is effective to reduce residual tumor growth or recurrence, but it is related with severe side effects. Another possibility is the clinical observation, or wait-to-see approach, but it is associated with tumor progression: 40% in 5-10 years. The efficacy of some medical treatment are not defined yet.

Since the identification of dopaminergic and somatostatinergic receptors in NFPA, the pharmacological treatment of the NFPA has been considered as a possibility for treatment. To date, clinical use of dopamine agonist (DA) in NFPA patients has been evaluated in some studies. However, these studies present modest and inconclusive results and the DA role in the NPFA management remains undefined.

In this study, the investigators plan a clinical trial designed to investigate the efficacy of cabergoline in NFPA individuals with remaining tumor after primary neurosurgery. These results could help to define the efficacy of DA in NFPA management.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pituitary Adenoma Nonfunctioning Pituitary Adenoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

A Single Center, Open Label and Randomized Clinical Trial.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study Group

This group received cabergoline, in a total week dose of 3.5 mg, starting 6 months after transphenoidal surgical approach with evidence of tumoral rest in MRI and pituitary adenoma hystopathological confirmation.

Group Type EXPERIMENTAL

Cabergoline

Intervention Type DRUG

Control Group

This group was followed, with clinical visits in same frequency of study group, but without intervention.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cabergoline

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

dostinex

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* presence of pituitary tumor rest at 6 months after neurosurgery
* absence of previous hormonal pituitary hypersecretion
* absence of previous radiotherapy and/or radiosurgery
* Histopathological exam showing pituitary adenoma

Exclusion Criteria

* ACTH immunoexpression at histopathological exam
* presence of previous radiotherapy and/or radio surgery
* psychotic psychiatric disease
* moderate or severe alterations in cardiac valves

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes